These data support clinical observations that plasma apoA-I levels are negative predictors of atherosclerosis but apoA-II levels are not [50] Our data also support a set of important studies which show that peptides derived from apoA-I have anti-inflammatory effects in vitro and in vivo [51–54]. Here, APOA1 is linked to atherosclerosis.